Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer
1
Department of Chemistry, Colorado State University, Fort Collins, CO 80521, USA
2
Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80521, USA
3
Department of Chemistry, Colorado State University, Campus Delivery 1872, Fort Collins, CO 80523, USA
4
School of Biomedical Engineering, Colorado State University, Fort Collins, CO 80523, USA
*
Author to whom correspondence should be addressed.
Diseases 2018, 6(4), 85; https://doi.org/10.3390/diseases6040085
Received: 20 August 2018
/
Revised: 12 September 2018
/
Accepted: 20 September 2018
/
Published: 22 September 2018
(This article belongs to the Section Oncology)
Determination of therapeutic efficacy is a major challenge in developing treatment options for cancer. Prior to in vivo studies, candidate therapeutics are evaluated using cell-based in vitro methods to assess their anti-cancer potential. This review describes the utility and limitations of evaluating therapeutic efficacy using human tumor-derived cell lines. Indicators for therapeutic efficacy using tumor-derived cell lines include cell viability, cell proliferation, colony formation, cytotoxicity, cytostasis, induction of apoptosis, and cell cycle arrest. Cell panel screens, 3D tumor spheroid models, drug-drug/drug-radiation combinatorial analysis, and invasion/migration assays reveal analogous in vitro information. In animal models, cellular assays can assess tumor micro-environment and therapeutic delivery. The utility of tumor-derived cell lines for efficacy determination is manifest in numerous commercially approved drugs that have been applied in clinical management of cancer. Studies reveal most tumor-derived cell lines preserve the genomic signature of the primary tumor source and cell line-based data is highly predictive of subsequent clinical studies. However, cell-based data often disregards natural system components, resulting in cell autonomous outcomes. While 3D cell culture platforms can counter such limitations, they require additional time and cost. Despite the limitations, cell-based methods remain essential in early stages of anti-cancer drug development.
View Full-Text
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Gordon, J.L.; Brown, M.A.; Reynolds, M.M. Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer. Diseases 2018, 6, 85. https://doi.org/10.3390/diseases6040085
AMA Style
Gordon JL, Brown MA, Reynolds MM. Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer. Diseases. 2018; 6(4):85. https://doi.org/10.3390/diseases6040085
Chicago/Turabian StyleGordon, Jenna L., Mark A. Brown, and Melissa M. Reynolds. 2018. "Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer" Diseases 6, no. 4: 85. https://doi.org/10.3390/diseases6040085
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
